Tedizolid is a novel oxazolidinone antimicrobial administered in its prodrug form, tedizolid 23 phosphate as a fixed once-daily dose. The pharmacokinetics of tedizolid has been studied in 24 relatively small proportion of morbidly obese (BMI ≥ 40 kg/m 2 ) adults through population 25 analyses with sparse sampling. The current study compared the intensively sampled plasma 26 pharmacokinetics of tedizolid phosphate and tedizolid in 9 morbidly obese to 9 age-, sex-, and 27 ideal body weight-matched non-obese (BMI 18.5 -29.9 kg/m 2 ) healthy adult (18-50 years of 28 age) volunteers after administration of a single-intravenous dose of tedizolid phosphate. The 29 median (range) weight was 72.6 (58.9-89.5) kg and 117 (102-176) kg in mostly female (77.8 %) 30 non-obese and morbidly obese adults, respectively. Tedizolid phosphate concentrations were 31 below the limit of quantitation in a majority of subjects after the 2-hour time point. The 32 tedizolid plasma median (range) C max and AUC 0-inf was 2.38 (1.28-3.99) mg/L and 26.3 (18.4-33 43.2) h•mg/L, respectively, in morbidly obese subjects that was non-significantly (p≥0.214) 34 different than values in non-obese subjects. Similarly, the volume of distribution (Vz, p=0.110) 35 and clearance (CL, p=0.214) were comparable between groups. A nearly identical (p=0.953) 36 median tedizolid half-life of approximately 12 hours was observed in both groups. Tedizolid Vz 37 and CL scaled with body weight but not proportionately. The small and non-significant 38 differences in tedizolid AUC 0-inf between morbidly obese and non-obese subjects suggest that 39 dose modification is not necessary in morbidly obese adults. are common in obese patients who are predisposed to developing type 2 diabetes (2). Tedizolid 43 is a novel once-daily oxazolidinone that was recently approved for the treatment of ABSSSI at 44 200 mg daily for 6 days. Tedizolid is a more potent oxazolidinone compared to linezolid and 45 does not interact with selective serotonin reuptake inhibitors (SSRIs). This pharmacological 46 difference is significant because use of antidepressants is higher in obese adults compared to 47 non-obese adults in the United States (3, 4). As a consequence, tedizolid may be selected over 48 linezolid for the treatment of ABSSSI in obese patients that are potentially managed with SSRIs. 49
To date, population pharmacokinetic (POP-PK) analyses have demonstrated that the 50 concentration-time profile of tedizolid is similar in subjects with class II obesity (BMI ≥ 35 51 kg/m 2 ) compared to non-obese adults (BMI < 30 kg/m 2 ), suggesting that no dose modification 52 for body size is necessary (5) . In addition, POP-PK analyses have clearly demonstrated that the 53 tedizolid volume of distribution and clearance scale as a power term function of ideal body 54 weight (IBW) but not with body weight or BMI (6). This POP-PK analysis suggests that identical 55 doses of tedizolid can be administered in obese and non-obese adult patients of similar stature 56 (6). However, the POP-PK model likely included a relatively small proportion of morbidly obese 57 (BMI ≥ 40 kg/m 2 ) adults as only one of two Phase 3 trials enrolled patients (27 of 664 subjects) 58 in this body size stratum (5-7). 59
Two Phase 3 studies, TR701-112 and TR701-113, evaluated the efficacy, safety, and 60 POP-PK of tedizolid 200 mg once daily for 6 days compared to linezolid 600 mg twice daily for 61 10 days (7 The 95% confidence interval for the response rate difference between these groups crossed 67 zero (not significant) but a trend in the size of the difference is notable across body size (7). A 68 subgroup analysis of the primary endpoint by medical history in the pooled studies showed that 69 patients with diabetes on tedizolid also had a numerically lower response rate compared to 70 patients on linezolid. Although the studies found tedizolid to be non-inferior to linezolid for the 71 primary efficacy outcome, the numerical differences in the diabetic and obese populations 72 cannot be ignored (7). The results of the analyses, albeit insufficiently powered, suggest the 73 potential for different outcomes in obese patients, especially among those with diabetes. 74
The results of these sub-group analyses prompt a closer examination of the tedizolid 75 dosing schedule in obese adults. The tedizolid AUC and C max is similar after single and multiple 76 doses of intravenous tedizolid that supports the role of a single-dose PK study to characterize 77 the concentration-time profile of this agent (8) . If the tedizolid pharmacokinetic parameters are 78 correlated to ideal body weight as suggested by POP-PK analyses, then similar exposures should 79 be expected in morbidly obese and non-obese adults with the same dosage. Thus, the current sampling was performed through a peripheral venous catheter in the arm contralateral to the 116 site of drug infusion. The study subjects were discharged from the clinical research unit after 117 the 12 hour sample, and returned to the site for subsequent sampling by peripheral venous 118 collection. All 5 mL blood samples were collected using K 3 EDTA blood collection tubes (BD, 119
Franklin Lakes, NJ, USA) to prevent ex-vivo conversion of tedizolid phosphate to tedizolid. Each 120 blood sample tube was inverted and made up-right 5 times to afford mixing of blood with the 121 anticoagulant, maintained on wet ice, and centrifuged at 1200 g for 10 minutes at 4°C within 122 60 minutes of collection. Plasma samples were stored frozen at -70°C until bioanalysis. Sample 123 analysis was performed by a validated method at Covance Laboratories (Madison, WI) as 124 previously described (8) . Briefly, tedizolid phosphate and tedizolid were assayed by tandem-125 liquid chromatography mass-spectrometry using labeled versions of both analytes as internal 126 
150
Subject demographics. A total of 19 subjects were enrolled into the study with one withdrawal 151 due to an intravascular infiltration during infusion of the dose. Demographic data based on the 152 body size categorical group are summarized in Table 1 . As expected based on the study 153 inclusion criteria, the mean body weight and body mass index were approximately 1.62 fold 154 higher in the morbidly obese compared to the non-obese group. In addition the mean body 155 surface area was 1.27 fold higher in the morbidly obese compared to the non-obese group. 156
Tedizolid phosphate concentration-time profile. Tedizolid phosphate concentrations were 157 measurable in all subjects at mid-point and end of the infusion but only measurable in 3 non-158 obese subjects and 1 morbidly obese subject at the 2-hour time point. The mean (standard 159 deviation) tedizolid phosphate concentration at the end of infusion was 1.73 (0.775) mg/L and 160 0.909 (0.417) mg/L that was significantly higher (p=0.0041) in non-obese compared to the 161 morbidly obese group, respectively. However, this potential difference was not relevant by the 162 2-hour time point given that the majority of subjects had concentrations below the LLOQ. The 163 limited detection of tedizolid phosphate concentrations in plasma is consistent with the 164 expectation of rapid conversion in plasma to tedizolid. Given the limited measurement profile 165 of tedizolid phosphate, pharmacokinetic analyses was not performed. 166
Tedizolid concentration-time profile. Tedizolid concentrations were measurable in all subjects 167 and followed a mono-exponential decline after the end of infusion. The mean and standard 168 deviation concentration-time profile of tedizolid is illustrated by the non-obese and morbidly 169 obese groups (Fig. 1) . As shown in this figure, mean concentrations were numerically higher 170 initially in non-obese subjects relative to the morbidly obese subjects. However, no significant 171 on August 29, 2017 by guest http://aac.asm.org/ Downloaded from 9 differences were observed between the C max , T max , C last , or T last measurements between the two 172 groups ( Table 2 ). The 200 mg dosage of tedizolid phosphate is equivalent to 164.5 mg of 173 tedizolid, and so this value was used to define the tedizolid dose (100% conversion assumed). 174
The median (range) values for the pharmacokinetic system parameters and measures of 175 exposure are also included in Table 2 . No statistically significant differences were observed 176 between the groups. The rapid decline in tedizolid phosphate concentrations by 2 hours 177 corresponded with a mean time to maximum concentration of 1.98 h and 1.42 h in non-obese 178 and morbidly obese subjects, respectively (p=0.214). Safety and tolerability. Three subjects experienced four adverse events in total. One subject 197 experienced an intravenous infiltration during the infusion. No action was required as the 198 infusion was terminated as soon as the adverse event was observed. Given the interruption in 199 the infusion and inability to define the dose received the subject was withdrawn from the study 200 after resolution of the adverse event. A subject experienced a headache that resolved with self-201 administration of ibuprofen. This subject also experienced six episodes of diarrhea that self-202 resolved by the end of the study visit. These two adverse events were judged by the study 203 physician to be probably related to the study drug. Finally, one subject experienced an ankle 204 injury secondary to a fall with no loss of consciousness. This event was self-managed by the 205 subject and deemed unrelated to the study drug. 206
207

DISCUSSION 208
This is the first study to directly compare the pharmacokinetics of tedizolid in morbidly obese 209 and non-obese adults. The study was performed to ascertain whether a dose adjustment of 210 tedizolid phosphate is necessary in morbidly obese adults to achieve comparable tedizolid 211 exposures compared to non-obese adults. The study was designed to match subjects by age, 212 sex, and ideal body weight (i.e. height) because previous analyses suggested that ideal body 213 weight was the optimal body size predictor of tedizolid pharmacokinetic system parameters. 214
This study demonstrates that morbidly obese subjects matched by these criteria have non-215 11 significant differences in tedizolid exposure despite having a 62.2% higher mean body weight 216 compared to non-obese subjects. Validation of this POP-PK expectation through this 217 independent study and evaluation is important because it helps to ensure that a fixed dosing 218 recommendation for tedizolid is reasonable across the wide adult patient weight range. 219
The plasma concentration-time profile of tedizolid was similar in the non-obese and morbidly 220 obese subjects. As expected with most drugs, the plasma C max was numerically lower in 221 morbidly obese subjects due to an expected increase in the volume of distribution. This finding is consistent with this study because IBW is a function of height and sex and is 227 related to weight as a supra-linear function. Ultimately, less than 37% of interindividual 228 variability of tedizolid Vz was explained by body weight. In simpler terms, a 65 kg and 130 kg 229 subject would be expected to have a Vz of 83.4 L and 118 L, respectively, which is a 26.3% 230 difference despite a 2-fold difference in body weight. Given that the pharmacodynamic effects 231 of tedizolid are not known to be correlated to Cmax, the practical implications of weight on Vz 232 would be limited. 233
Similarly with this single dose study, the mean AUC was approximately 20% lower in the 234 morbidly obese subjects but this difference is not statistically significant. These results are 235 consistent with the demonstration that tedizolid clearance scales with weight 
